The drug can be effectiveif expensive, and often not covered by insuranceand addressing obesity early can prevent serious health problems later in life
Tirzepatide activates both GLP-1 and GIP receptors, while Semaglutide primarily targets GLP-1 receptors
NICE guidance (NG12) recommends urgent referral for investigation of dysphagia at any age Persistent vomiting that prevents adequate fluid or food intake, risking dehydration Vomiting blood (haematemesis) or passing black, tarry stools (melaena), which may indicate gastrointestinal bleeding New or significantly worsened heartburn or regurgitation that does not respond to usual reflux medications Right upper quadrant pain, fever, or jaundice , which may indicate gallbladder disease (cholelithiasis or cholecystitis) Severe abdominal pain with bloating and constipation , which could suggest intestinal obstruction or ileus Unexplained weight loss beyond expected therapeutic effects, or inability to maintain adequate nutrition
Typically, a company
The patient was prescribed dulaglutide 1.5 mg five weeks later, but never filled the prescription due to cost
Additionally, it slows gastric emptying, helping to control glucose levels and prevent spikes after meals